NEUROPSYCHOLOGICAL DISORDERS AND QUALITY OF LIFE IN WOMEN WITH METABOLIC SYNDROME
Keywords:
metabolic syndrome, women, cognitive impairment, anxiety, depression, stress, quality of life, MoCA, HADS, EQ-5D.Abstract
Metabolic syndrome (MetS) is a multifactorial condition associated with obesity, insulin resistance, dyslipidemia and arterial hypertension. In recent years, increasing attention has been paid to the relationship between metabolic abnormalities and neuropsychological disorders. Cognitive impairment, anxiety, depressive symptoms, stress and sleep disturbances may occur in patients with MetS and can significantly reduce quality of life.
The aim of this study is to assess the relationship between neuropsychological disorders and health-related quality of life in women with metabolic syndrome.
A prospective comparative study is planned involving women with MetS and an age-matched control group without MetS. Clinical and neurological examinations will be performed. Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA) and, when indicated, Addenbrooke’s Cognitive Examination III (ACE-III). Anxiety and depressive symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS) and Depression Anxiety Stress Scale-21 (DASS-21). Health-related quality of life will be evaluated using the EQ-5D questionnaire. Biochemical parameters, including glucose, glycated hemoglobin, lipid profile, insulin, homocysteine and C-reactive protein, will also be analyzed.
It is expected that women with MetS will demonstrate a higher frequency of cognitive and affective disturbances and lower quality-of-life scores compared with women without MetS. The severity of neuropsychological symptoms is expected to correlate with metabolic abnormalities and quality-of-life impairment.
Early identification of neuropsychological disorders may improve individualized management and contribute to better quality of life in women with metabolic syndrome.
References
1. Alberti K.G.M.M., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome. Circulation. 2009;120:1640–1645.
2. Grundy S.M. Metabolic syndrome update. Trends in Cardiovascular Medicine. 2016;26:364–373.
3. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
4. Yates K.F., Sweat V., Yau P.L., Turchiano M.M., Convit A. Impact of metabolic syndrome on cognition and brain. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:2060–2067.
5. Nasreddine Z.S., Phillips N.A., Bédirian V., et al. The Montreal Cognitive Assessment. Journal of the American Geriatrics Society. 2005;53:695–699.
6. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 1983;67:361–370.
7. Lovibond P.F., Lovibond S.H. The structure of negative emotional states. Behaviour Research and Therapy. 1995;33:335–343.
8. Herdman M., Gudex C., Lloyd A., et al. Development and preliminary testing of EQ-5D-5L. Quality of Life Research. 2011;20:1727–1736.
